SB-267268, a nonpeptidic antagonist of αvβ 3 and αvβ5 integrins, reduces angiogenesis and VEGF expression in a mouse model of retinopathy of prematurity

Investigative Ophthalmology and Visual Science

Volumn 47, Issue 4, 2006, Pages 1600-1605

  Wilkinson Berka, Jennifer L ^a   Jones, Daria ^a   Taylor, George ^a   Jaworski, Kassie ^a   Kelly, Darren J ^a   Ludbrook, Steve B ^b   Willette, Robert N ^b   Kumar, Sanjay ^b   Gilbert, Richard E ^a,c  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b GLAXOSMITHKLINE   (United States)

^c ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHAVBETA5 INTEGRIN; PROTEIN INHIBITOR; SB 267268; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; VITRONECTIN RECEPTOR; ANGIOGENESIS INHIBITOR; BENZAZEPINE DERIVATIVE; INTEGRIN; MESSENGER RNA; SB-267268; VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ADHESION; CELL MIGRATION; CONTROLLED STUDY; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; HUMAN CELL; IN SITU HYBRIDIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROLENTAL FIBROPLASIA; SMOOTH MUSCLE FIBER; ANIMAL; C57BL MOUSE; CELL MOTION; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MACACA; METABOLISM; NEWBORN; PREGNANCY; RAT; RETINA NEOVASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; BENZAZEPINES; CELL ADHESION; CELL MOVEMENT; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INFANT, NEWBORN; INTEGRIN ALPHAVBETA3; INTEGRINS; MACACA; MICE; MICE, INBRED C57BL; PREGNANCY; RATS; RECEPTORS, VITRONECTIN; RETINAL NEOVASCULARIZATION; RETINOPATHY OF PREMATURITY; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 33645988568     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.05-1314     Document Type: Article

References (37)

1. Brooks PC. Role of integrins in angiogenesis. Eur J Cancer. 1996;32A:2423-2429.
2. Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell. 1992;69:11-25.
3. Giancotti FG, Ruoslahti E. Integrin signaling. Science. 1999;285:1028-1032.
4. Luna J, Tobe T, Mousa SA, et al. Antagonists of integrin alpha v beta 3 inhibit retinal neovascularization in a murine model. Lab Invest. 1996;75:563-573.
5. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science. 1994;264:569-571.
6. Brooks PC, Montgomery AM, Rosenfeld M, et al. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 1994;79:1157-1164.
7. Brooks PC, Stromblad S, Klemke R, et al. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest. 1995;96:1815-1822.
8. Hutcheson KA. Retinopathy of prematurity. Curr Opin Ophthalmol. 2003;14:286-290.
9. Fong DS, Aiello L, Gardner TW, et al. Retinopathy in diabetes. Diabetes Care. 2004;27(Suppl 1):S84-87.
10. Pierce EA, Avery RL, Foley ED, et al. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci USA. 1995;92:905-909.
11. Moravski CJ, Kelly DJ, Cooper ME, et al. Retinal neovascularization is prevented by blockade of the renin-angiotensin system. Hypertension. 2000;36:1099-1104.
12. Friedlander M, Theesfeld CL, Sugita M, et al. Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases. Proc Natl Acad Sci USA. 1996;93:9764-9769.
13. Miller WH, Keenan RM, Willette RN, et al. Identification and in vivo efficacy of small-molecule antagonists of integrin alphavbeta3 (the vitronectin receptor). Drug Discov Today. 2000;5:397-408.
14. Wilkinson-Berka JL, Alousis NS, Kelly DJ, et al. COX-2 inhibition and retinal angiogenesis in a mouse model of retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2003;44:974-979.
15. Wong A, Hwang SM, McDevitt P, et al. Studies on alpha v beta 3/ligand interactions using a [3H]SK&F-107260 binding assay. Mol Pharmacol. 1996;50:529-537.
16. Kumar CS, James IE, Wong A, et al. Cloning and characterization of a novel integrin beta3 subunit. J Biol Chem. 1997;272:16390-16397.
17. Yue TL, McKenna PJ, Ohlstein EH, et al. Osteopontin-stimulated vascular smooth muscle cell migration is mediated by beta 3 integrin. Exp Cell Res. 1994;214:459-464.
18. Sarlos S, Rizkalla B, Moravski CJ, et al. Retinal angiogenesis is mediated by an interaction between the angiotensin type 2 receptor, VEGF, and angiopoietin. Am J Pathol. 2003;163:879-887.
19. Friedlander M, Brooks PC, Shaffer RW, et al. Definition of two angiogenic pathways by distinct alpha v integrins. Science. 1995;270:1500-1502.
20. Hammes HP, Brownlee M, Jonczyk A, et al. Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization. Nat Med. 1996;2:529-533.
21. Chavakis E, Riecke B, Lin J, et al. Kinetics of integrin expression in the mouse model of proliferative retinopathy and success of secondary intervention with cyclic RGD peptides. Diabetologia. 2002;45:262-267.
22. Riecke B, Chavakis E, Bretzel RG, et al. Topical application of integrin antagonists inhibits proliferative retinopathy. Horm Metab Res. 2001;33:307-311.
23. Casaroli Marano RP, Preissner KT, Vilaro S. Fibronectin, laminin, vitronectin and their receptors at newly-formed capillaries in proliferative diabetic retinopathy. Exp Eye Res. 1995;60:5-17.
24. Yasukawa T, Hoffmann S, Eichler W, et al. Inhibition of experimental choroidal neovascularization in rats by an alpha(v)-integrin antagonist. Curr Eye Res. 2004;28:359-366.
25. Storgard CM, Stupack DG, Jonczyk A, et al. Decreased angiogenesis and arthritic disease in rabbits treated with an alphavbeta3 antagonist. J Clin Invest. 1999;103:47-54.
26. Stromblad S, Becker JC, Yebra M, et al. Suppression of p53 activity and p21WAF1/CIP1 expression by vascular cell integrin alphaVbeta3 during angiogenesis. J Clin Invest. 1996;98:426-433.
27. Coleman KR, Braden GA, Willingham MC, et al. Vitaxin, a humanized monoclonal antibody to the vitronectin receptor (alphavbeta3), reduces neointimal hyperplasia and total vessel area after balloon injury in hypercholesterolemic rabbits. Circ Res. 1999;84:1268-1276.
28. Gutheil JC, Campbell TN, Pierce PR, et al. Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3. Clin Cancer Res. 2000;6:3056-3061.
29. Zhang H, Li C, Baciu PC. Expression of integrins and MMPs during alkaline-burn-induced corneal angiogenesis. Invest Ophthalmol Vis Sci. 2002;43:955-962.
30. Connolly SE, Hores TA, Smith LE, et al. Characterization of vascular development in the mouse retina. Microvasc Res. 1988;36:275-290.
31. Ferrara N. Vascular endothelial growth factor and the regulation of angiogenesis. Recent Prog Horm Res. 2000;55:15-35; discussion 35-16.
32. Yan Q, Li Y, Hendrickson A, et al. Regulation of retinal capillary cells by basic fibroblast growth factor, vascular endothelial growth factor, and hypoxia. In Vitro Cell Dev Biol Anim. 2001;37:45-49.
33. Yamada H, Yamada E, Kwak N, et al. Cell injury unmasks a latent proangiogenic phenotype in mice with increased expression of FGF2 in the retina. J Cell Physiol. 2000;185:135-142.
34. Stone J, Itin A, Alon T, et al. Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. J Neurosci. 1995;15:4738-4747.
35. Alon T, Hemo I, Itin A, et al. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med. 1995;1:1024-1028.
36. Borges E, Jan Y, Ruoslahti E. Platelet-derived growth factor receptor beta and vascular endothelial growth factor receptor 2 bind to the beta 3 integrin through its extracellular domain. J Biol Chem. 2000;275:39867-39873.
37. Soldi R, Mitola S, Strasly M, et al. Role of alphavbeta3 integrin in the activation of vascular endothelial growth factor receptor-2. EMBO J. 1999;18:882-892.